- Home
- SRPT vs ARQT Comparison
SRPT vs ARQT Comparison
Compare SRPT & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRPT
- ARQT
- Stock Information
- Founded
- SRPT 1980
- ARQT 2016
- Country
- SRPT United States
- ARQT United States
- Employees
- SRPT N/A
- ARQT N/A
- Industry
- SRPT Biotechnology: Pharmaceutical Preparations
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- SRPT Health Care
- ARQT Health Care
- Exchange
- SRPT Nasdaq
- ARQT Nasdaq
- Market Cap
- SRPT 1.7B
- ARQT 1.7B
- IPO Year
- SRPT 1997
- ARQT 2020
- Fundamental
- Price
- SRPT $18.19
- ARQT $13.78
- Analyst Decision
- SRPT Buy
- ARQT Strong Buy
- Analyst Count
- SRPT 25
- ARQT 6
- Target Price
- SRPT $64.00
- ARQT $18.80
- AVG Volume (30 Days)
- SRPT 7.9M
- ARQT 2.0M
- Earning Date
- SRPT 08-06-2025
- ARQT 08-13-2025
- Dividend Yield
- SRPT N/A
- ARQT N/A
- EPS Growth
- SRPT N/A
- ARQT N/A
- EPS
- SRPT N/A
- ARQT N/A
- Revenue
- SRPT $2,233,371,000.00
- ARQT $212,819,000.00
- Revenue This Year
- SRPT $26.87
- ARQT $61.15
- Revenue Next Year
- SRPT $3.15
- ARQT $37.98
- P/E Ratio
- SRPT N/A
- ARQT N/A
- Revenue Growth
- SRPT 59.15
- ARQT 100.03
- 52 Week Low
- SRPT $16.88
- ARQT $7.86
- 52 Week High
- SRPT $155.95
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- SRPT 23.09
- ARQT 46.51
- Support Level
- SRPT $16.88
- ARQT $13.51
- Resistance Level
- SRPT $18.62
- ARQT $14.31
- Average True Range (ATR)
- SRPT 1.40
- ARQT 0.61
- MACD
- SRPT 0.09
- ARQT -0.01
- Stochastic Oscillator
- SRPT 6.41
- ARQT 46.95
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.